

## <u>Fax Transmission</u> Transmission de télécopieur

From / De: Tania-Elena Di Millo-Briganti	To/A: Shyam Nair GM Technical Sales for Ansapack Pvt Ltd
Date: 2012-09-27 08:37:34 AM Pages: 3	FAX Number / Numéro de télécopieur: 011912223006409

Subject/Sujet: DMF 2012-197 for Packaging Material

Dear Sir or Madam,

As a part of our efforts to improve Drug Master File (DMF) client services and to reduce response transit times to clients we are now faxing letters of acknowledgement. You are receiving this fax because you have recently submitted a New DMF registration for processing at Health Canada's DMF Administration Unit.

Please find enclosed one letter of acknowledgement in response to your New DMF Registration for DMF 2012-197.

Please note that we will no longer be mailing the letters of acknowledgement for requested DMF administrative services.

## It would be greatly appreciated if you could confirm receipt of this fax by way of a reply to my e-mail stated below.

Thank you for understanding as we navigate this transition.

Regards,

## Tania-Elena Di Millo-Briganti

Drug Master Files Administration Unit/Division des Fiches Maitresses de medicaments

Office of Submissions & Intellectual Property Division / Bureau des politiques sure les presentations et de la propriete intellectuelle

Address Locator/Localisateur Addresse 0201D

Therapeutic Products Directorate/Direction des produits therapeutiques

Health Products and Food Branch / Directions generalle des produits de sante et des aliments

Health Canada/Sante Canada


Phone/Tel: (613) 957-6813

Fax: (613) 957-3989

 ${\it Email/Courriel: Tania-Elena. Di. Millo-Briganti@hc-sc.gc.ca}$ 



HEALTH-#27167-v1-DMF\_2012-197\_\_\_PACKAGING\_MATERIAL NEW DMF,DOC



Health Canada
Therapeutic Products Directorate
DMF Administration Unit
Address Locator 0201D
101 Tunney's Pasture Driveway
Ottawa, Ontario
K1A 0K9
Canada

DMF 2012-197

OF2-28-11-2012197

September 27, 2012

Shyam Nair G.M. Technical Sales ANSAPACK PVT LTD. 1st Floor, Simplex Mills Compound K.K. Marg, Byculla (West) Mumbai 400 011 India

Dear Shyam Nair:

**RE: Packaging Material** 

We are acknowledging receipt of the company letter dated September 15, 2012 and the material listed below for Packaging Material, which has been assigned the number DMF 2012-197.

Drug Master Files (DMFs) will only be reviewed in connection with drug submissions from sponsors for whom you have provided a letter of authorization; therefore, this acknowledgement should <u>not</u> be considered as an approval of the content of your Drug Master File.

Please note that Health Canada has received the following:

- 1. Payment of \$400.00 Cdn. for new Drug Master File registration
- 2. 1 binder
- 3. 1 CD
- 4. Statement of commitment

Please refer to the Health Canada website for the new amended fees as of April 1<sup>st</sup>, 2012, including the stipulation of a new two percent annual increase effective each April 1<sup>st</sup>. <a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/fees-frais/index-eng.php#master">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/fees-frais/index-eng.php#master</a>

.../2

Canada

Health Canada is moving toward an electronic format for Drug Master Files; as such, we would appreciate a copy of your Drug Master File(s) and subsequent updates to be sent as PDF files on a CD to supplement the paper copy.

We would like to take this opportunity to remind DMF Owners and Agents that they are responsible for all costs associated with shipping documents and electronic information to Health Canada, including any applicable customs and/or brokerage fees. Packages must indicate "Terms DDP (Delivered Duty Paid)". Any packages submitted to Health Canada with a request for additional charges by a shipper or brokerage firm will be returned to sender at the sender's expense. Thank you for your attention to this matter.

For Type I DMFs (pertaining to active pharmaceutical ingredients), you are reminded that a copy of the open part must be provided to the sponsor of a drug submission that cross-references the DMF.

The open part of Type I DMFs may, therefore, be subject to discussions between the Therapeutic Products Directorate (TPD) and the submission sponsor for whom you have authorized Health Canada to access your DMF.

The closed part of Type I DMFs and all parts of Types II, III and IV DMFs will be kept confidential.

If any comments are considered necessary concerning the closed part of Type I DMFs or all parts of Types II, III and IV DMFs, they will be forwarded directly to the DMF Owner. In this case, the submission sponsor may be notified that there are outstanding issues that must be addressed before the DMF can be considered to support their drug submission.

It is recommended that Drug Master Files be updated every two years in order to keep these files open and active. Any changes or additions to the Drug Master File should be forwarded to the DMF Administration Unit as soon as possible.

If you have further questions on the administration of the Drug Master Files, please e-mail dmf enquiries@he-sc.gc.ca.

Yours sincerely,

Tania-Elona Di Millo-Briganti

Tania-Elena Di Millo-Briganti DMF Administration Unit